Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement

Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In this study, we developed a GCN-based deep learning model (CocrystalGCN) for i...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Fu Xiao, Yinxiang Cheng, Jian-Rong Wang, Dingyan Wang, Yuanyuan Zhang, Kaixian Chen, Xuefeng Mei, Xiaomin Luo
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2022-10-01
Reeks:	Pharmaceutics
Onderwerpen:	bexarotene cocrystal prediction GCN bioavailability
Online toegang:	https://www.mdpi.com/1999-4923/14/10/2198
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!